Enterprise Value

99.07M

Cash

83.52M

Avg Qtr Burn

-19.79M

Short % of Float

0.00%

Insider Ownership

12.13%

Institutional Own.

16.71%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
UCART22 Details
Acute lymphoblastic leukemia, Rare genetic disease, Cancer, B-cell acute lymphoblastic leukemia

Phase 1

Data readout

UCART123 Details
Cancer, Relapsed/refractory acute myeloid leukemia

Phase 1

Data readout

UCARTCS1 Details
Cancer, Multiple myeloma, Menkes Disease

Phase 1

Data readout

UCART19 (anti-CD19) Details
Cancer, Multiple myeloma, Acute lymphoblastic leukemia

Failed

Discontinued

ALLO-501 Details
Non-Hodgkin lymphoma, Cancer

Failed

Discontinued

ALLO-715 Details
Cancer, Multiple myeloma

Failed

Discontinued